Specificity Determinants of Allosteric Modulation in the Neuronal Nicotinic Acetylcholine Receptor: a Fine Line between Inhibition and Potentiation

Laura C. Cesa, Colin A. Higgins, Steven R. Sando, Dennis W. Kuo, and Mark M. Levandoski

Department of Chemistry, Grinnell College, Grinnell, Iowa

Received September 21, 2011; accepted November 4, 2011

ABSTRACT

We are interested in the allosteric modulation of neuronal nicotinic acetylcholine receptors (nAChRs). We have postulated that the anthelmintic morantel (Mor) positively modulates (potentiates) rat α3β2 receptors through a site located at the β(+)/α(−) interface that is homologous to the canonical agonist site (Neurosci 29:8734–8742, 2009). On this basis, we aimed to determine the site specificity by studying differences in modulation between α3β2 and α4β2 receptors. We also compared modulation by Mor with that of the related compound oxantel (Oxa), whereas Mor and Oxa each potentiated α3β2 receptors 2-fold at saturating acetylcholine (ACh) concentrations, Mor had no effect on α4β2 receptors, and Oxa inhibited ACh-evoked responses. The inhibition was noncompetitive, but not due to open channel block. Furthermore, the nature and extent of modulation did not depend on subunit stoichiometry. We studied six positions at the α(−) interface that differ between α3 and α4. Two positions (α3Ile57 and α3Thr115) help mediate the effects of the modulators but do not seem to contribute to specificity. Mutations in two others (α3Leu1107 and α3Ile117) yielded receptors with appreciable α4-character; that is, Mor potentiation was reduced compared with wild-type α3β2 control and Oxa inhibition was evident. A fifth position (α3Glu113) was unique in that it discriminated between the two compounds, showing no change in Mor potentiation from control but substantial Oxa inhibition. Our work has implications for rational drug design for nicotinic receptors and sheds light on mechanisms of allosteric modulation in nAChRs, especially the subtle differences between potentiation and inhibition.

Introduction

The neuronal nicotinic acetylcholine receptors (nAChRs) are a diverse family of ligand-gated ion channels and are members of the Cys-loop superfamily. They are implicated in neurological disorders such as Alzheimer's and Parkinson's diseases (Albuquerque et al., 2009). Perhaps more importantly, nAChRs have a central role in nicotine abuse, because nicotine increases the activation of reward pathways (Dani and Bertrand, 2007). The clinical successes of drugs such as varenicline for smoking cessation (e.g., Gonzales et al., 2006) and galantamine in reducing cognitive impairments associated with Alzheimer's (Birks, 2006) suggest promise for pharmacological interventions targeting central cholinergic systems. Although nAChRs containing α7 or α4β2 subunits have been a focus of drug development, specific roles for nAChRs in physiological processes and well-defined nAChR subtypes remain unclear (e.g., Gotti et al., 2009); thus, the search for new nAChR ligands is still broad (Jensen et al., 2005).

Substantial recent interest has focused on allosteric modulators of nAChRs (Bertrand and Gopalakrishnan, 2007). Such compounds enhance or inhibit channel activity from binding sites that are noncompetitive with the canonical (orthosteric) agonist site. Some positive modulators have the advantageous property of being at most weak partial agonists. Thus, their potentiation of responses elicited by endogenous ACh may allow for temporal and spatial coincidence activation in cholinergic pathways, thereby avoiding the tonic activation expected for drugs that are full agonists (Maelicke and Albuquerque, 2000).

Several novel compounds and their allosteric modulatory effects have been reported. Examples include N-(5-chloro-2,4-
dimethoxyphenyl)-N’-(5-methyl-3-isoxazolyl)-urea (PNU-120596) (Hurst et al., 2005) acting on α7 receptors, KAB-18 (Henderson et al., 2010) acting on αβ2 receptors, and [2-(4-fluorophenyl)amino]-4-methyl-5-thiazolo]-3-thiencyl methane (LY-2087101) with a less selective profile (Broad et al., 2006). In addition, a variety of previously known compounds act as allosteric modulators, such as the anticeptolycheolinesterases galanthamine and physostigmine (e.g., Schrattenholz et al., 1996) and the anthelmintic ivermectin (Krause et al., 1998). We and others have shown that other anthelmintic compounds that are full agonists in lower species, causing spastic paralysis in the worm, also allosterically potentiate human and rat nAChRs (e.g., Bartos et al., 2006; Wu et al., 2008).

Localizing ligand binding sites is of primary concern for a complete understanding of allosteric modulators—and is crucial for any rational drug design efforts. The identification and elaboration of the canonical agonist and competitive antagonist binding site at the α(+)/non-α(−) interface of the receptor extracellular domain is a well-developed aspect of the nAChR field (Arias, 2000; Sine and Engel, 2006). Work based on X-ray crystal structures of the nAChR extracellular domain homolog acetylcholine binding protein, as well as a model of the entire muscle-type receptor and homology modeling thereof, has enriched our understanding of receptor ligand interactions (e.g., Rucktooa et al., 2009). This information is now being employed to determine binding sites for allosteric modulators of nAChRs (e.g., Nirthanan et al., 2008; Collins and Millar, 2010). Although technical limitations and subtype diversity together currently preclude an atomic-resolution picture of many neuronal nAChR systems of interest, the available models still have very strong predictive power in guiding structure-function studies of nAChRs.

On the basis of our studies of anthelmintics as allosteric modulators, we proposed as a general feature of the receptors that nAChR ligand “pseudo-sites” occur at the noncanonical subunit interfaces [e.g., β(3)/α(3) for morantel (Mor); Seo et al. (2009)]. From this premise, several important questions about the nature of these sites arise: which features are common to both canonical and noncanonical sites, thus constituting a generalized nAChR ligand site, and which features differentiate canonical (agonist/competitive antagonist) from noncanonical (modulator) sites? What are the determinants of specificity for allosteric modulators acting on different receptor subtypes? Such questions seem of increasing importance given the recent demonstration that the α(+)/α(−) interface in α4(β2)2 receptors constitutes a low-sensitivity agonist site (Harpse et al., 2011; Mazzafar et al., 2011). The answers to such questions are one of the keys to the development of therapeutic agents against neuropathologic conditions involving nicotinic receptors. In this study, we identify the determinants of specificity of the β2(3)/α3(−) modulator site and discover that modulation can be interconverted between potentiation and inhibition by point mutations.

Materials and Methods

Reagents. All chemicals used, unless otherwise noted, were reagent grade and obtained from Sigma-Aldrich (St. Louis, MO). Morantel is 1,4,5,6-tetrahydro-1-methyl-2-[2-[3-methyl-2-thienyl](ethenyl)]pyrimidine, tartrate salt. Oxantel is 1-methyl-2-[3-(3-hydroxyphenyl)ethenyl]-1,4,5,6-tetrahydropyrimidine, with 4-methylenebis(3-hydroxy-2-naphthoic acid). Pyrantel is 1-methyl-2-[2-thienyl](ethenyl]-1,4,5,6-tetrahydropy-

rimidine, with tartrate salt. Methanethiosulfonate (MTS) reagents were purchased from Toronto Research Chemicals (Toronto, ON, Canada). Those used in this study were [2-(trimethylammonium)ethyl]-methanethiosulfonate and imidazole 4-methyl methanethiosulfonate.

Nicotinic Receptor Clones and Mutagenesis. Plasmids of the pGEMHE background bearing wild-type rat α3 and β2 cDNA sequences were a gift from Dr. Charles Luetje (Miami University, Miami, FL); the clones were originally isolated in the lab of Dr. Jim Patrick (Baylor College of Medicine, Houston, TX) (Boulter et al., 1987). Mutant genes were created either by 1) the QuikChange site-directed mutagenesis method (Stratagene, La Jolla, CA) with complementary primers harboring the mutation or 2) custom mutagenesis from GenScript (Piscataway, NJ). Mutations were verified by complete sequencing of the entire extracellular domain region using capillary electrophoresis of dye-detected, deoxy-generated fragments. Unless otherwise noted in the context of another receptor subtype, all α3 and β2 residue numbering follows that in the structure a3b2rr.pdb (http://www.ebi.ac.uk/compneur-srv/LGICdb/HTML/a3b2rr.html) (Sallette et al., 2004); these position numbers are smaller by two compared with numbering used elsewhere in the literature; this discrepancy has arisen because of homology modeling based on a crystal structure of a protein of different sequence. The cDNAs were linearized with a unique restriction enzyme, and then were made RNase-free by phenol-chloroform extraction. RNAs were synthesized from these cDNAs using the T7 kit from Ambion (Austin, TX). RNAs were diluted with RNase-free water to 0.5 μg/μl and stored at −20°C.

Oocyte Preparation and Injection. Functional receptors were expressed in Xenopus laevis oocytes harvested from oocyte-positive female frogs or whole ovary tissue (Nasco, Ft. Atkinson, WI) using procedures approved by the Grinnell College Institutional Animal Care and Use Committee in accord with the National Institutes of Health guidelines. In brief, stage V to VI oocytes were prepared by collagenase treatment and manual selection. Oocytes were maintained at 16°C in Barth’s medium (88 mM NaCl, 1.0 mM KCl, 2.5 mM NaHCO3, 0.30 mM Ca(NO3)2, 0.41 mM CaCl2, 0.82 mM MgSO4, 15 mM HEPES, and 2.5 mM sodium pyruvate, pH 7.6, supplemented with 100 U/ml penicillin/streptomycin and 50 μg/ml gentamicin). With the use of a Nanoject microinjector (Drummond, Broomall, PA), each oocyte was injected with 46 nl of a 1:1 (v/v) combination of the desired α and β subunits, prepared from 0.5 μg/μl stock solutions. In a subset of experiments, 1:10 or 1:10 combinations (v/v); total of 46 nl per oocyte) were injected in accordance with previous work (Zwart and Vijverberg, 1998; Moroni et al., 2008). Allowing 2 to 4 days for receptor expression, with daily changes of Barth’s medium and removal of dead cells, currents could be recorded for up to 7 subsequent days. Expression for all mutants was comparable with that for the wild-type α3β2 and α4β2 receptors as judged by currents in the range 0.2 to 4 μA evoked with a saturating ACh concentration (3 mM); expression seemed to depend more on the donor/injection batch than on subtype. Likewise, current traces for all mutants, including the triple and quintuple combinations, were very similar to those of wild-type α3β2 (and not α4β2; see Fig. 1A) at the same effective concentrations; this observation suggests that neither the mutations nor the modulators greatly affected the desensitization properties of the receptors, consistent with our previous results (Wu et al., 2008).

Macroscopic Current Recordings. Electrophysiology recordings were made with a Gene Clamp 500B amplifier ( Molecular Devices, Sunnyvale, CA) to measure evoked currents from oocytes using the two-electrode voltage-clamp method, according to previous work (Wu et al., 2008; Seo et al., 2009). Voltage was clamped at −60 mV, with leak currents <200 nA, although larger leak currents were occasionally tolerated in the presence of a stable baseline. Perfusion and drug administration were controlled with solenoid valve systems (VC-6; Warner Instruments, Hamden, CT). Recording electrodes were filled with 3 M KCl and selected for resistances between 0.5 and 5 MΩ. Each oocyte was perfused with drug for 5 s and washed with oocyte Ringer’s medium (OR2; 115 mM NaCl, 2.5 mM KCl, 1.8 mM
We are interested in a class of anthelmintic compounds that includes morantel, pyrantel, and oxantel (structures in Fig. 1A) as a model of allosteric modulation of neuronal nicotinic acetylcholine receptors (nAChRs). Having previously determined that Mor potentiation was quite specific for α3β2 receptors (both rat and human; Wu et al., 2008), we carried out a limited structure-activity relationship study with these three anthelmintics. The two key results from this approach are demonstrated by the representative traces shown in Fig. 1A. First, whereas Mor and Pyr potentiated ACh-evoked currents for α3β2 receptors, there was little to no effect of these compounds on α4β2 receptors when coapplied with ACh. Second, although Oxa potentiated α3β2 responses in the same manner as Mor and Pyr, it inhibited α4β2 ACh-evoked currents.

Because the degree of potentiation is a strong function of both agonist and modulator concentration (Wu et al., 2008), we explored the full concentration-response behavior for the
three anthelmintics on both α3β2 and α4β2 nAChRs. As shown in Fig. 1B, the three compounds potentiated ACh-evoked currents in a quantitatively indistinguishable manner; each of the three parameters characterizing the Hill equation fits are the same within error across the three drugs (see Table 1 and the legend to Fig. 1). It is noteworthy that these compounds potentiated at saturating concentrations of agonist (I_{modulator}/I_{control} ~ 2.3), a macroscopic indication of increased efficacy of channel gating (Wu et al., 2008).

In contrast, Mor and Pyr failed to potentiate α4β2 responses (Fig. 1C); Hill equation fits for the modulator-added condition are indistinguishable from their matched-pair ACh-alone controls (Table 1; Fig. 1 legend). We were surprised to find that 10 μM Oxa inhibited all ACh-evoked currents across this range, with an 18-fold decrease in potency for the evoked response. The increased Hill slope and decreased maximum response (at the highest ACh concentrations) are immediate indications that Oxa inhibits α4β2 receptors noncompetitively (Rang, 1981; Colquhoun, 1998). In addition to the fit to the entire data set denoting a decreased efficacy (E_{max} = 0.85 ± 0.13), the ACh + Oxa responses at 1 and 3 mM ACh were significantly smaller than those of controls (t test; p < 0.05). At this level of analysis, Mor and Pyr had identical behavior; we therefore focused only on identifying the origins of the differences between Mor and Oxa.

We next investigated in more detail the mechanism of Oxa inhibition of α4β2 responses. Figure 2A demonstrates that, although inhibition of ACh-evoked currents increased with increasing Oxa concentration, the currents could not be completely eliminated under these conditions (100 μM ACh ~ EC_{70}), as would be expected for competitive inhibition. This incomplete inhibition is unlikely to arise from Oxa insolubility, because the highest concentrations we used are well below the maximum solubility under these conditions (see Materials and Methods). Many nAChR ligands are positively charged and inhibited by an open channel blocking mechanism at high concentration (Buisson and Bertrand, 1998; Arias et al., 2006). We therefore measured Oxa inhibition of α4β2 as a function of membrane holding potential. As can be seen in Fig. 2B, Oxa inhibition was not strongly voltage-dependent and, if anything, showed a slight increase as the cell was depolarized. This behavior is opposite that expected for an open channel blocker, the inhibition by which becomes more severe at hyperpolarized potentials because of the increased driving force to cross the membrane (Buisson and Bertrand, 1998). Note also that the degree of inhibition was greater for the lower (100 μM) ACh concentration at all potentials measured; this behavior is also opposite that expected for competitive and open channel block mechanisms (Rang, 1981).

Numerous studies have demonstrated that the stoichiometry of α4 and β2 subunits in heterologously expressed receptors dictates their response to agonists and antagonists, as well as allosteric modulators (e.g., Zwart and Vijverberg, 1998; Moroni et al., 2008). We therefore measured Oxa inhibition of α4β2 receptors as a function of the ratio of the subunit RNAs injected, in accordance with the previous work cited above in choosing the ratios 10:1 and 1:10. Figure 2C shows that Oxa inhibition is substantial throughout the

### TABLE 1

<table>
<thead>
<tr>
<th>Subtype</th>
<th>ACh Response</th>
<th>Modulation Response</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EC_{50} [μM]</td>
<td>n</td>
</tr>
<tr>
<td>α3β2</td>
<td>66 ± 9</td>
<td>0.75 ± 0.07 [5–11]</td>
</tr>
<tr>
<td>α4β2</td>
<td>21 ± 4</td>
<td>0.59 ± 0.06 [6–12]</td>
</tr>
<tr>
<td>α3W53Aβ2</td>
<td>42 ± 2</td>
<td>1.08 ± 0.06 [6–10]</td>
</tr>
<tr>
<td>α3β2βW149A</td>
<td>40 ± 6</td>
<td>0.99 ± 0.12 [5]</td>
</tr>
<tr>
<td>α3K109Fβ2</td>
<td>86 ± 14</td>
<td>0.66 ± 0.07 [12]</td>
</tr>
<tr>
<td>α3L107Cβ2</td>
<td>62 ± 7</td>
<td>0.71 ± 0.06 [6–9]</td>
</tr>
<tr>
<td>α3L107Hβ2</td>
<td>27 ± 4</td>
<td>1.02 ± 0.13 [17]</td>
</tr>
<tr>
<td>α3E113Rβ2</td>
<td>40 ± 5</td>
<td>1.01 ± 0.12 [10]</td>
</tr>
<tr>
<td>α3T115Cβ2</td>
<td>120 ± 20</td>
<td>0.71 ± 0.07 [9]</td>
</tr>
<tr>
<td>α3T115Qβ2</td>
<td>280 ± 40</td>
<td>0.96 ± 0.12 [5–10]</td>
</tr>
<tr>
<td>α3I117Tβ2</td>
<td>16 ± 2</td>
<td>0.93 ± 0.08 [15]</td>
</tr>
<tr>
<td>α3I57Kβ2</td>
<td>110 ± 10</td>
<td>0.83 ± 0.05 [7]</td>
</tr>
<tr>
<td>α3o4[3]β2</td>
<td>22 ± 4</td>
<td>0.93 ± 0.13 [9]</td>
</tr>
<tr>
<td>α3o4[5]β2</td>
<td>20 ± 3</td>
<td>1.15 ± 0.19 [10]</td>
</tr>
</tbody>
</table>
range of ACh concentrations tested, including at saturation (~1 mM). Comparison with Fig. 1C reveals that Oxa inhibition of the 10:1 and 1:10 combinations is qualitatively the same as the 1:1 subunit RNA ratio. Furthermore, we obtained the same result (equivalent Oxa inhibition) when we coexpressed wild-type α4 with the β2 (+) mutant β2T150C in 10:1 and 1:10 ratios (data not shown). Although the degree of inhibition of the 10:1 and 1:10 α4:β2 combinations may differ slightly from one another and from the 1:1 ratio, these results suggest that both α and β subunits are necessary for the effect (see also below) and that the different modes of modulation by Mor and Oxa do not arise because each compound acts preferentially on a receptor isoform of different stoichiometry.

Chemical modification studies of a series of cysteine-substituted residues provided evidence that Mor binds to the β(+)/α(-) interface, in a pocket structurally homologous to the canonical/agonist binding site (Seo et al., 2009). In particular, both tryptophans and two of the three tyrosines of the so-called aromatic box (Arias, 2000; Sine and Engel, 2006) are conserved in this interface. We therefore sought to substantiate that tryptophans 149 of β2 and 53 of α3 (see Fig. 4) play a role in allosteric modulation by these antihelmintics. As shown in Fig. 3, the concentration-response experiments for αβ2W149A receptors support this idea. In contrast to the very large degree of potentiation by Mor and Oxa on wild-type αβ2 receptors, both modulators gave mild inhibition of the ACh response. We found nearly identical results with the α3W53Aβ2 mutant (Table 1). It is noteworthy that both tryptophan-to-alanine mutants responded to ACh just as well as wild-type receptors (each has slightly larger nH; Table 1), indicating that the loss of Mor and Oxa potentiation does not arise from a general impairment of receptor function.

Given this further support for a modulator binding site located near, and possibly involving, β2Trp149 and α3Trp53, we turned our attention to elucidating the specificity differences between α3- and α4-containing receptors and between Mor and Oxa. Figure 4 shows a homology structural model of the β(+)/α(-) interface (Sallette et al., 2004), based on the acetylcholine binding protein X-ray crystal structure (Brejc et al., 2001), and an alignment of the rat α3 and α4 sequences for the equivalent of loops D and E from the canonical binding site. We reasoned that residues differing in the two subunits give rise to the specificity differences; those we selected for study are color-coded with the side chains shown in the
The noncanonical interfaces of α3β2 and α4β2 diverge. A homology model of the extracellular domain β2(+/α3(−)) interface is shown in ribbon format; β2 (left) is green and α3 (right) is gold. The tryptophan side chains (magenta, Trp149 of β2 and Trp53 of α3) conserved in the canonical/agonist binding site are shown in stick format. Below the structure is an alignment of the rat α3 and α4 sequences in the regions of the D and E loops. The side chains (stick format) chosen for specificity studies are color-coded in the α3 sequence; numbering is for the mature α3 protein. This depiction is derived from a3b2rr.pdb (Sallette et al., 2004).

Figure 4. The noncanonical interfaces of α3β2 and α4β2 diverge. A homology model of the extracellular domain β2(+)/α3(−) interface is shown in ribbon format; β2 (left) is green and α3 (right) is gold. The tryptophan side chains (magenta, Trp149 of β2 and Trp53 of α3) conserved in the canonical/agonist binding site are shown in stick format. Below the structure is an alignment of the rat α3 and α4 sequences in the regions of the D and E loops. The side chains (stick format) chosen for specificity studies are color-coded in the α3 sequence; numbering is for the mature α3 protein. This depiction is derived from a3b2rr.pdb (Sallette et al., 2004).

structure (Fig. 4). Note that the residues differing between α3 and α4 alternate with residues identical in the two, and that these identical amino acids are largely hydrophobic in character. This observation is consistent with the structural prediction that these stretches form β-strands with the hydrophobic residues directed toward the interior and that the alternating residues constitute diverse surfaces in this region for the two subunits (compare Teissère and Czajkowski, 2001).

Figure 5 illustrates the effects of substituting α4 residues into the α3 subunit for three of the six positions we examined. For the mutants α3L107H, α3E113R, and α3L117T (Fig. 5, A–C, respectively), the ACh-control concentration-response behavior was quite similar to that for wild-type α3β2 (see Table 1), although the parameters trended toward the α4 behavior. Again, these results indicate that the mutations do not significantly disrupt receptor function. In contrast to the wild-type–like ACh activation for these three mutants, each had a different pattern of response for Mor and Oxa modulation.

Mor potentiation was markedly reduced in α3L107Hβ2 compared with wild-type α3β2 (Fig. 5A) but not to the extent seen in wild-type α4β2. Our standard test concentration of 10 μM Oxa was only slightly inhibitory for α3L107Hβ2, but this behavior was considerably closer to that of α4 considering that Oxa substantially potentiates α3 responses at this concentration. A 5-fold higher Oxa concentration gave more α4-like inhibition, with a 4-fold decrease in potency and a significant increase in the Hill coefficient (Table 1). We also studied α3L107Cβ2, the cysteine substitution in this position (Table 1). Its behavior on the whole was quite similar to that of wild-type α3β2, in particular maintaining potentiation by both Mor and Oxa; note the leftward-shifted EC50 values relative to ACh alone and Emax values >1.5. Although cysteine is polar and smaller than leucine, it does not introduce an aromatic group or the expected positive charge of the α4-based histidine substitution. After treatment with MTS reagents that introduce either a fixed positive charge or an imidazole group, currents evoked by ACh + Mor or ACh + Oxa in α3L107Cβ2 were reduced relative to controls, indicating that the position is accessible to the reagent and involved in modulation (L.C.C. and M.M.L., unpublished observations). Together, our results are on the mutant α3L107Hβ2 and α3L107Cβ2 receptors strongly support a role of this position in modulation by Mor and Oxa.

In contrast to the α3Leu107T position, the mutation in position 113 (glutamate → arginine) showed marked discrimination between Mor and Oxa. Mor potentiation for α3E113Rβ2 was nearly identical to that of wild-type α3β2 (Fig. 5B; Table 1), although it had a slightly lower maximum effect at saturating agonist concentrations. However, Oxa effects were much more like wild-type α4β2, with a 2-fold rightward shift of EC50 and increased nH relative to control. In addition, 10 μM Oxa inhibited ACh-evoked currents (side-by-side measurements; paired t test, p < 0.05) at all concentrations but the highest (3 mM).

The α3I117Tβ2 receptors had yet a third profile, with modulation by Mor and by Oxa much more like wild-type α4 than α3 receptors, without discriminating between the two (Fig. 5C; Table 1). Not only was Mor potentiation abolished for this receptor but also Mor inhibited at nonsaturating ACh concentrations. Likewise, similar to wild-type α4, Oxa inhibited most at lower ACh concentrations, shifting the response curve to the right with a 3-fold increase in EC50.

We also studied three other positions in the α3 loop D and E regions. The best-fit parameters for these mutants are given in Table 1. The α3K109F substitution removes a positive charge and introduces an aromatic moiety. Despite this substantial change in physical character, Mor and Oxa still potentiated the ACh response to an extent similar to that of wild-type α3β2, if not better. The impact of another charge substitution—neutral and nonpolar to negatively charged—in the α3I57Eβ2 receptor was similar. Both Mor and Oxa potentiated the receptor with substantial 18-fold leftward shifts in EC50 for the concentration-response curve relative to ACh alone activation (compare 6-fold for wild-type α3β2). However, the overall improvement in efficacy in the presence of the modulator was less than that for the wild type, as indicated by Emax of 1.7 versus 2.6 for Mor and 1.2 versus 2.3 for Oxa. Finally, two mutations at position 115 of α3 gave rather surprising results. For substitutions of the α3 threonine with cysteine and with the α4-based glutamine, both Mor and Oxa still potentiated ACh-evoked responses; the leftward shift in EC50 (relative to ACh control) ranged from 13- to 125-fold. Although the relative efficacy of both modulators was approximately the same as wild-type α3β2 receptors for α3T115Cβ2 (a fairly conservative substitution), the Emax increased for both in the case of α3T115Qβ2. Along with our previous demonstration of substantial effects of MTS modification on Mor activity for α3T115Cβ2 (See et al., 2009), these results support a role of position 115 in modulation of these receptors. However, this position does not seem to discriminate between the two compounds.
Not surprisingly, no single mutation that we studied converted α3 to α4 in terms of its modulation, so we next sought to generate α4-like modulation with combination mutants. To this end, we made α3/α4[3], the triple mutant α3L107H/E113R/I117T, and α3/α4[5], the quintuple mutant that adds α3T115Q and α3I157E to the triple mutant. Again we measured the effects of 10 μM Mor or 10 μM Oxa on the ACh concentration response for these mutant subtypes (Fig. 6). There were no apparent adverse effects of these mutations in combination on receptor function (for example, on protein folding or receptor assembly), as suggested by ACh-concentration-response behavior similar to that of the two wild-type receptors (Table 1) and by typical expression levels (evoked current magnitudes). In fact, the α3-based combination mutants interestingly had ACh responses very similar to those of wild-type α4β2, indicating an impact of this interface in channel activation (compare Seo et al., 2009). Both combination mutants also had Mor and Oxa modulation behavior more like that of α4 than of any of the single mutants but with some interesting differences (Table 1). The Mor-added condition gave ACh responses indistinguishable from those of control for the two combination mutants; that is, Mor did not potentiate these mutants. For the α3/α4[3] construct, the Oxa-added titration resulted in an EC50 shifted to lower potency (approximately 3-fold) and an efficacy much lower than control ($E_{\text{max}} \sim 0.5$); this efficacy was also lower than for Oxa inhibition of wild-type α4 receptors. Although the potency shift for the Oxa-added condition was larger at 4-fold for α3/α4[5], the efficacy was the same as in wild-type α4β2 receptors ($E_{\text{max}} = 0.88$) but, importantly, was less than control response.

To confirm that Oxa inhibits the α3 mutant receptors by the same mechanism as it does α4β2 receptors, we also studied the voltage-dependence of Oxa inhibition. These results are shown in Fig. 7A, which is a plot of the degree of inhibition as a function of holding potential. For the three point mutants showing the greatest α4-character (Fig. 5), we studied Oxa inhibition at two ACh concentrations. As was the case for wild-type α4β2, these data sets have effectively zero slopes. The only exception was the condition of 100 μM ACh for α3I117Tβ2 (Δ), which showed a shallow negative slope. We found similar results for the two combination mutants (data not shown in Fig. 7A for clarity). As was the case with Oxa inhibition of wild-type α4β2 receptors, these results are contrary to an open channel block mechanism.

Likewise, we confirmed that changing the subunit stoichiometry of α3-based receptors does not substantially alter Oxa inhibition. Figure 7B shows that Oxa inhibited indistinguishably receptors expressed by coinjecting the triple mutant α3/α4[3] and wild-type α2β2 RNAs in ratios of 10:1 and 1:10. As was the case with wild-type α4β2 receptors, different subunit stoichiometries do not seem to give rise to different modes of modulation by Mor and Oxa.
Discussion

We studied the effects of mutations at the noncanonical /H9252/(\textit{H}11001)/H9251/(\textit{H}11002) interface on the allosteric modulation of neuronal nicotinic receptors by anthelmintic compounds. Our results support our previous hypothesis that this interface constitutes the modulator binding site, and we have identified several residues in the rat /H9251/3 subunit that not only give rise to the subunit specificity for these compounds but also discriminate between Mor and Oxa. We have also unexpectedly discovered that modulation in this system can shift between the extremes of potentiation and inhibition with ostensibly minor structural changes in the receptor.

The Modulator Binding Site. Our data and previous reports in the literature support the conclusion that the \(\beta(+)/\alpha(-)\) interface contains an allosteric modulator binding

![Fig. 6. Combination mutants have \(\alpha4\) character. Concentration-response behavior for the two combination mutants are shown; \(\alpha3/\alpha4[3]\) (A) is the triple mutant \(\alpha3L107H/E113R/I117T\) and \(\alpha3/\alpha4[5]\) (B) is the quintuple mutant \(\alpha3I57E/L107H/E113R/T115Q/I117T\). Data were analyzed as described in Figs. 3 and 5 with the parameters for the fits reported in Table 1. The replicates were as follows: \(n = 4\) (+ Mor, \(\square\) and dashed curve), \(n = 5\) (+ Oxa, \(\bigcirc\) and dotted curve) for \(\alpha3/\alpha4[3]\) (A); and \(n = 4\) (+ Mor, \(\square\) and dashed curve), \(n = 6\) (+ Oxa, \(\bigcirc\) and dotted curve), and \(n = 10\) (ACh controls, \(\blacksquare\) and solid curve) for \(\alpha3/\alpha4[5]\) (B).

![Fig. 7. Oxantel inhibition of \(\alpha3\) mutants is noncompetitive and independent of subunit stoichiometry. A, the fractional degree of Oxa inhibition \(\left(\frac{I_{\text{ACH}}}{I_{\text{ACH}} - I_{\text{Oxa}}}/I_{\text{ACH}}\right)\) is plotted versus holding potential for three point mutants \((\alpha3\alpha4[3]\), squares; \(\alpha3\alpha4[5]\), circles; \(\alpha3\alpha4[5]\), triangles). In all cases, the filled and open symbols represent the lower (20 \(\mu\text{M}\)) and higher (100 \(\mu\text{M}\)) ACh concentrations, respectively. Control and Oxa coapplied responses at each ACh concentration were recorded on the same set of oocytes; the Oxa concentration was 10 \(\mu\text{M}\) for \(\alpha3\alpha4[3]\) and \(\alpha3\alpha4[5]\) and 50 \(\mu\text{M}\) for \(\alpha3\alpha4[5]\). Symbols represent means (+ S.E.M.) for \(n = 3\) or 4; in some cases, error bars are smaller than the symbol. B, the effect of subunit stoichiometry on Oxa inhibition of the triple mutant \(\alpha3/\alpha4[5]\) is shown. Responses evoked by ACh alone are shown as \(\blacksquare\) (10:1 RNA injection ratio) and \(\bigstar\) (1:10), whereas responses to ACh + 10 \(\mu\text{M}\) Oxa are given as \(\triangle\) (10:1) and \(\square\) (1:10). All currents were normalized to the response to 1.5 mM ACh alone; values plotted are means (+ S.E.M.) for \(n = 3\) or 4; in some cases, error bars are smaller than the symbol. B, the effect of subunit stoichiometry on Oxa inhibition of the triple mutant \(\alpha3/\alpha4[5]\) is shown. Responses evoked by ACh alone are shown as \(\blacksquare\) (10:1 RNA injection ratio) and \(\bigstar\) (1:10), whereas responses to ACh + 10 \(\mu\text{M}\) Oxa are given as \(\triangle\) (10:1) and \(\square\) (1:10). All currents were normalized to the response to 1.5 mM ACh alone; values plotted are means (+ S.E.M.) for \(n = 3\) or 4; in some cases, error bars are smaller than the symbol.
site. As shown in Fig. 3 and Table 1, mutation of the two highly conserved tryptophans (α3W53A and β2W149A) abolished the potentiation by Mor and Oxa seen in wild-type α3β2. Although it is tempting to interpret these results as substantially reducing modulator affinity (thereby supporting a direct role in binding), the effects are no doubt more complicated (for example, the 2.5-fold increase in EC_{50} for ACh activation and \( E_{\text{max}} = 0.90 \) in the presence of Oxa indicate inhibition).

We demonstrated previously that residues in this interface, particularly β2Thr150 and α3Thr115, contribute to allosteric potentiation (Seo et al., 2009). The gross structural homology of this interface pocket to the canonical agonist site and the fact that four of the five residues of the "aromatic box" are conserved further substantiate this as a ligand binding site. In addition, Hsiao et al. (2006) and Moroni et al. (2008) found that residues in this same vicinity of noncanonical interfaces in neuronal nAChRs are responsible for modulation by divalent cations.

Furthermore, the modulation of nAChRs by anthelmintic compounds parallels that of GABA_{A} receptors by benzodiazepines, the noncanonical interface binding sites of which are well established (e.g., Miller and Smart, 2010). For example, radioligand binding assays, evoked-current measurements, and chemical modification experiments for receptors with mutations in these positions indicate that γ2Thr81, γ2Arg132, and γ2Thr142 play roles in benzodiazepine/hypnotic binding or modulation (Kucken et al., 2000; Teissère and Czajkowski, 2001; Hanson et al., 2008). These residues are homologous to the α3Ile57, α3Leu107, and α3Ile117 nAChR residues, respectively, found to govern Mor and Oxa activities (Figs. 5 and 6; Table 1). Although it is possible that Mor and Oxa bind elsewhere to the nicotinic receptor, all our results are consistent with a binding site at the β+/γ(-) interface. This demonstration suggests that five (potential) interface ligand binding sites are a general feature of the Cys-loop receptor superfamily.

**Specificity of Modulation.** The major goal of this study was to understand the specificity of modulator-binding site interactions. Our limited structure-activity relationship design, exploring both the compounds and subunits, yielded specificity information about both. Five of the six positions identified in these loop D and E equivalents, and we indicated by the combination mutants (Fig. 6).

**Switching the Modulation Mechanism.** How can we explain our findings in a comprehensive way, especially in regard to a mechanistic switch between potentiation and inhibition? Noncanonical interfaces govern modulation of α4-containing receptors by divalent cations, but whether the modulation is inhibition or potentiation seems to depend on the receptor stoichiometry (Hsiao et al., 2006; Moroni et al., 2008). In our studies, altering the ratio of injected subunit RNAs did not change Oxa inhibition substantially for either wild-type or mutant receptors (Figs. 2 and 7). This suggests that differential subunit stoichiometry selectivity cannot explain the differences in Mor and Oxa modulation, which is consistent with our general conclusion that Mor/Oxa modulation requires both α and β subunits.

We demonstrated previously that Mor potentiates α3β2 by enhancing gating efficacy, probably by increasing the rate of channel opening (Wu et al., 2008), similar to the finding that zinc enhances α4 channel open probability through increased burst duration (Hsiao et al., 2008). In other words, a Mor-bound receptor favors the open state of the channel preferentially over the closed state, relative to the control of activation by ACh alone. We are intrigued by an observation for all the mutants in the current study that the shift in EC_{50}
and $E_{\text{max}}$ in the presence of Mor or Oxz were each correlated with the shift in $EC_{50}$ for Ach activation relative to wild-type a3β2. For example, the mutations α3L157E and α3T115Q reduced Ach potency, and potentiation was greater than for the wild-type a3β2 receptor, whereas α3L107H, α3117T, and the triple and quintuple combinations increased Ach potency, and potentiation was greatly reduced or inhibition obtained (Table 1). If the modulator, when bound, establishes approximately the same closed ↔ open equilibrium independent of other factors, then inhibition (which we found to be noncompetitive; Figs. 2 and 7) is merely a decrease in efficacy relative to control. Further work is required to substantiate this mechanism, for example, by finding mutations in this region of a3 that would yield definitive Mor inhibition, as well as recording single-channel activity to measure efficacy directly.

Our work indicates that adjacent residues can favor either the closed or open state of the receptor and that such residues are located in the complementary (−) side of binding site interfaces. In light of previous studies, neither of these ideas is surprising. Collins and Millar (2010) demonstrated that mutations clustered in the transmembrane domain of a7 receptors could convert potentiation by ivermectin into inhibition. Likewise, many studies support a role of the complementary face of the canonical binding site in channel activation (e.g., Mukhtasimova and Sine, 2007; Young et al., 2007). That such apparently important contributions to gating arise in the noncanonical interfaces (our work) raises questions about the symmetry requirements of activation for nAChRs (compare Rayes et al., 2009). Likewise, mapping the spatial distribution of residues promoting channel opening versus closing in this region may help illuminate how subunits move in converting between these conformations (Corringer et al., 2010). In addition to these issues fundamental to ion channel function, our work suggests a very specific region of a3 and a4 nAChRs to target for drug design.

Acknowledgments

We thank Ria Laureijs for pilot studies and early discussions of the project, Annie Campbell for administrative assistance, and Paul Christman for technical assistance. We thank the reviewers of a previous submission for their valuable suggestions.

Authorship Contributions

Participated in research design: Cesa, Higgins, Sando, Kuo, and Levandoski.

Conducted experiments: Cesa, Higgins, Sando, Kuo, and Levandoski.

Contributed new reagents or analytic tools: Cesa, Higgins, Sando, Kuo, and Levandoski.

Performed data analysis: Cesa, Higgins, Sando, Kuo, and Levandoski.

Wrote or contributed to the writing of the manuscript: Cesa, Higgins, Sando, Kuo, and Levandoski.

References


Collins T and Millar NS (2010) Nicotinic acetylcholine receptor transmembrane mutations convert ivermectin from a positive to a negative allosteric modulator. Mol Pharmacol 78:188–204.


cation of binding sites in the nicotinic acetylcholine receptor for TDBél-etomidate, a photoreactive positive allosteric effector. *J Biol Chem* **283**:22051–22062.


Address correspondence to: Mark Levandoski, Department of Chemistry, 1116 8th Avenue Grinnell, IA 50112. E-mail: levandos@grinnell.edu